DaShenLin Pharmaceutical Group Statistics

Total Valuation

DaShenLin Pharmaceutical Group has a market cap or net worth of CNY 16.40 billion. The enterprise value is 19.25 billion.

Market Cap	16.40B
Enterprise Value	19.25B

Important Dates

The next estimated earnings date is Tuesday, April 29, 2025.

Earnings Date	Apr 29, 2025
Ex-Dividend Date	Oct 23, 2024

Share Statistics

DaShenLin Pharmaceutical Group has 1.14 billion shares outstanding. The number of shares has decreased by -0.25% in one year.

Current Share Class	n/a
Shares Outstanding	1.14B
Shares Change (YoY)	-0.25%
Shares Change (QoQ)	+3.17%
Owned by Insiders (%)	64.55%
Owned by Institutions (%)	9.75%
Float	403.75M

Valuation Ratios

The trailing PE ratio is 19.23 and the forward PE ratio is 15.72.

PE Ratio	19.23
Forward PE	15.72
PS Ratio	0.62
PB Ratio	2.39
P/TBV Ratio	12.04
P/FCF Ratio	11.02
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 6.86, with an EV/FCF ratio of 12.94.

EV / Earnings	22.65
EV / Sales	0.73
EV / EBITDA	6.86
EV / EBIT	13.97
EV / FCF	12.94

Financial Position

The company has a current ratio of 0.92, with a Debt / Equity ratio of 0.90.

Current Ratio	0.92
Quick Ratio	0.56
Debt / Equity	0.90
Debt / EBITDA	2.61
Debt / FCF	4.92
Interest Coverage	5.91

Financial Efficiency

Return on equity (ROE) is 11.53% and return on invested capital (ROIC) is 5.96%.

Return on Equity (ROE)	11.53%
Return on Assets (ROA)	3.64%
Return on Capital (ROIC)	5.96%
Revenue Per Employee	583,716
Profits Per Employee	18,701
Employee Count	45,466
Asset Turnover	1.12
Inventory Turnover	4.13

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -43.64% in the last 52 weeks. The beta is 0.30, so DaShenLin Pharmaceutical Group's price volatility has been lower than the market average.

Beta (5Y)	0.30
52-Week Price Change	-43.64%
50-Day Moving Average	15.80
200-Day Moving Average	16.61
Relative Strength Index (RSI)	33.35
Average Volume (20 Days)	8,589,809

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, DaShenLin Pharmaceutical Group had revenue of CNY 26.54 billion and earned 850.26 million in profits. Earnings per share was 0.75.

Revenue	26.54B
Gross Profit	9.01B
Operating Income	1.38B
Pretax Income	1.22B
Net Income	850.26M
EBITDA	1.60B
EBIT	1.38B
Earnings Per Share (EPS)	0.75

Full Income Statement

Balance Sheet

The company has 5.72 billion in cash and 7.32 billion in debt, giving a net cash position of -1.60 billion or -1.40 per share.

Cash & Cash Equivalents	5.72B
Total Debt	7.32B
Net Cash	-1.60B
Net Cash Per Share	-1.40
Equity (Book Value)	8.13B
Book Value Per Share	6.03
Working Capital	-1.08B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 3.20 billion and capital expenditures -1.71 billion, giving a free cash flow of 1.49 billion.

Operating Cash Flow	3.20B
Capital Expenditures	-1.71B
Free Cash Flow	1.49B
FCF Per Share	1.31

Full Cash Flow Statement

Margins

Gross margin is 33.95%, with operating and profit margins of 5.19% and 3.20%.

Gross Margin	33.95%
Operating Margin	5.19%
Pretax Margin	4.58%
Profit Margin	3.20%
EBITDA Margin	6.03%
EBIT Margin	5.19%
FCF Margin	5.61%

Dividends & Yields

This stock pays an annual dividend of 0.62, which amounts to a dividend yield of 4.31%.

Dividend Per Share	0.62
Dividend Yield	4.31%
Dividend Growth (YoY)	n/a
Years of Dividend Growth	2
Payout Ratio	43.91%
Buyback Yield	0.25%
Shareholder Yield	4.56%
Earnings Yield	5.20%
FCF Yield	9.07%

Dividend Details

Stock Splits

The last stock split was on June 9, 2023. It was a forward split with a ratio of 1.2.

Last Split Date	Jun 9, 2023
Split Type	Forward
Split Ratio	1.2

Scores

DaShenLin Pharmaceutical Group has an Altman Z-Score of 2.17. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.17
Piotroski F-Score	n/a